These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29377216)

  • 21. Featured Article: Serum [Met
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
    Oaks Z; Stage A; Middleton B; Faraone S; Johnson B
    Discov Med; 2018 Nov; 26(144):197-206. PubMed ID: 30695679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?
    Ramanathan S; Panksepp J; Johnson B
    Psychosomatics; 2012; 53(6):591-4. PubMed ID: 22480625
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
    Li Z; You Y; Griffin N; Feng J; Shan F
    Int Immunopharmacol; 2018 Aug; 61():178-184. PubMed ID: 29885638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
    Beaudry H; Gendron L; Morón JA
    Eur J Neurosci; 2015 Apr; 41(7):901--7. PubMed ID: 25639561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review.
    Hatfield E; Phillips K; Swidan S; Ashman L
    J Am Dent Assoc; 2020 Dec; 151(12):891-902.e1. PubMed ID: 33228882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
    Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
    Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.
    Shannon A; Alkhouri N; Mayacy S; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2010 Sep; 16(9):1457. PubMed ID: 20014017
    [No Abstract]   [Full Text] [Related]  

  • 29. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
    Toljan K; Vrooman B
    Med Sci (Basel); 2018 Sep; 6(4):. PubMed ID: 30248938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for opioids in the treatment of fibromyalgia?
    Littlejohn GO; Guymer EK; Ngian GS
    Pain Manag; 2016 May; 6(4):347-55. PubMed ID: 27296831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lowdown on low-dose naltrexone.
    Shabeeb N
    Cutis; 2020 Jan; 105(1):E17-E18. PubMed ID: 32074159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.
    Ekelem C; Juhasz M; Khera P; Mesinkovska NA
    JAMA Dermatol; 2019 Feb; 155(2):229-236. PubMed ID: 30484835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review.
    Soin A; Soin Y; Dann T; Buenaventura R; Ferguson K; Atluri S; Sachdeva H; Sudarshan G; Akbik H; Italiano J
    Pain Physician; 2021 Jul; 24(4):E393-E406. PubMed ID: 34213865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibromyalgia.
    Johnson J; Sheth S
    J Pain Palliat Care Pharmacother; 2016 Sep; 30(3):233-4. PubMed ID: 27636677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.
    Rupp A; Young E; Chadwick AL
    Pain Med; 2023 Nov; 24(11):1270-1281. PubMed ID: 37302106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
    Berg BJ; Pettinati HM; Volpicelli JR
    Drug Saf; 1996 Oct; 15(4):274-82. PubMed ID: 8905252
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.